Defense Stock Domin...
Health Care: Drugs
Discovery Laboratories Inc. (DSCO: NASDAQ)
$1.63 0.00 | 0.00%
05/24/13 - 12:10 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 195.00K | 582.00K | 0.00 | 0.00 |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 195.00K | 582.00K | 0.00 | 0.00 |
| Selling, General, and Administrative Expenses | 16.44M | 7.86M | 8.39M | 10.12M |
| Research & Development | 21.57M | 17.23M | 17.14M | 19.08M |
| Operating Income before D & A (EBITDA) | -37.82M | -24.51M | -25.53M | -29.20M |
| Depreciation & Amortization | 1.15M | 1.23M | 1.55M | 1.99M |
| Interest Income | 6.00K | 13.00K | 288.00K | 39.00K |
| Other Income - Net | 555.00K | 3.56M | 6.42M | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -38.41M | -22.17M | -20.37M | -31.15M |
| Interest Expense | 57.00K | 26.00K | 357.00K | 1.08M |
| Pre-Tax Income | -38.46M | -22.20M | -20.72M | -32.23M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -37.32M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -37.32M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -37.32M | -20.96M | -19.18M | -30.24M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-37.32M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -37.32M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.95 | -0.93 | -1.65 | -3.90 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.95 | -0.93 | -1.65 | -3.90 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.95 | -0.93 | -1.65 | -3.90 |
| Basic Normalized Net Income/Share | -0.95 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.95 | -0.93 | -1.65 | -3.90 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.95 | -0.93 | -1.65 | -3.90 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.95 | -0.93 | -1.65 | -3.90 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.95 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with DSCO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserKJP Spring Break
- ContributorStocks Under-$10 Setting Up...
- UserSmall Cap Stocks
- Userjet189 Portfolio 1
- Uservolume spike
- Usermoon_in_mood Portfolio 1
- UserDtech Portfolio 1
Latest DSCO Headlines from TheStreet
- 5 Stocks Under $10 Set to Explode 02.14.13 | 01:02 pm
- Discovery Labs Receives New US Patent For Pulmonary Surfactant Formulations 01.17.13 | 07:01 am
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- Discovery Labs To Present At The Stifel Nicolaus Healthcare Conference 2012 09.04.12 | 07:09 am
- 8 Stocks Under $10 Surging Higher 08.28.12 | 02:08 pm
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 5 Stocks Under $10 Poised for Upside 04.27.12 | 11:04 am
- For Biotech Takeovers, Timing is Key 04.04.12 | 06:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
Press Releases for DSCO
- Discovery Labs Announces Completion Of $14.25 Million Public Offering - PR Newswire 05.15.13 | 10:05 am
- Discovery Labs Prices $14.25 Million Public Offering Of Common Stock - PR Newswire 05.10.13 | 08:05 am
- Discovery Labs Announces Proposed Public Offering Of Common Stock - PR Newswire 05.09.13 | 04:05 pm
- Discovery Labs Announces Recent AFECTAIR® Publications - PR Newswire 05.01.13 | 07:05 am
- Discovery Labs Receives FDA Recommendations And Request For Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications - PR Newswire 04.15.13 | 07:04 am
- Discovery Labs Announces Newly-Released SURFAXIN® (lucinactant) Publications - PR Newswire 03.29.13 | 07:03 am
- Discovery Labs To Report Fourth Quarter 2012 Results And Hold Conference Call On Wednesday, March 13, 2013 - PR Newswire 03.06.13 | 04:03 pm
- Discovery Labs Receives $30 Million Funding Commitment From Deerfield Management - PR Newswire 02.13.13 | 04:02 pm
- Discovery Labs Announces Changes To Board Of Directors And Appoints A New Chief Executive Officer - PR Newswire 01.04.13 | 08:01 am
- Discovery Labs Initiates Launch Of AFECTAIR® - PR Newswire 01.03.13 | 07:01 am
Partner Headlines for DSCO
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Discovery Labs Down 17% After Public Offering Announcement - Benzinga 03.16.12 | 09:03 am
- Company News for March 8, 2012 - Corporate Summary - Zacks 03.08.12 | 10:03 am
- Discovery Labs Up 33% After Surfaxin Approved by the FDA - Benzinga 03.07.12 | 09:03 am
- Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome - Benzinga 03.06.12 | 04:03 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- UPDATE 1-Discovery Labs' cystic fibrosis drug gets orphan status - Reuters 11.01.10 | 08:11 am
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial - Reuters 06.09.10 | 08:06 am
- FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma - Seeking Alpha 05.20.10 | 06:05 am
